Ranbaxy has had so much regulatory action by FDA it has its own FDA page--

Regulatory Action Against Ranbaxy

Consent Decree for Toansa, India, Facility

• FDA Press Release¹:  FDA prohibits Ranbaxy’s Toansa, India facility from producing and distributing drugs for the U.S. market (1/23/2014)
• FDA Form 483 (PDF - 8.44MB)² (1/11/2014)

 

Import Alert and Consent Decree for Mohali, India, Facility

• FDA Press Release³: FDA prohibits manufacture of FDA-regulated drugs from Ranbaxy’s Mohali, India, plant and issues import alert (9/16/2013)
• FDA Form 483 (PDF – 2MB)⁴ (9/11/2012)
• FDA Form 483 (PDF – 785KB)⁵ (12/7/2012)

   

Department of Justice Action Against Ranbaxy

• DOJ News Release⁶: Generic Drug Manufacturer Ranbaxy Pleads Guilty and Agrees to Pay $500 Million to Resolve False Claims Allegations, CGMP Violations and False Statements to the FDA (5/13/2013)

Consent Decree for Paonta Sahib, Batamandi, and Dewas, India, Facilities and Ohm Laboratories in Gloversville, N.Y.

• FDA News Release⁷: Department of Justice files consent decree of permanent injunction against Ranbaxy (1/25/2012)

 

Application Integrity Policy Action for Paonta Sahib, India, Facility

• FDA AIP Letter to Ranbaxy Laboratories⁸ (updated 3/2/2009)
• FDA News Release⁹: FDA Takes New Regulatory Action Against Ranbaxy’s Paonta Sahib Plant in India (2/25/2009)
• Application Integrity Policy List¹⁰

 

Import Alert for Dewas and Paonta Sahib, India, Facilities

• FDA News Release¹¹: FDA Issues Warning Letters to Ranbaxy Laboratories Ltd., and an Import Alert for Drugs from Two Ranbaxy Plants in India (9/16/2008)
• List of Drugs Manufactured at the Dewas and Paonta Sahib Facilities of Ranbaxy Laboratories, Ltd. ¹²
• Questions and Answers ¹³
• Warning Letter Dewas, India ¹⁴
• Warning Letter Batamandi (Unit II), in Paonta Sahib, India ¹⁵

Additional Warning Letters

• Ohm Laboratories, Inc.¹⁶ (12/21/2009)
• Paonta Sahib, India¹⁷ (6/15/2006)
• Princeton, NJ¹⁸ (10/11/2002)

quoted from here